

Measurement Period for Denominators and Numerators for the 2025 Adult Core Set Measures

Measure	2025 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
AIS-AD: Adult Immunization Status	January 1, 2024 – December 31, 2024 (Denominator includes beneficiaries age 19 and older at the start of the measurement period, January 1, 2024.)	<p>Influenza Rate: July 1, 2023 – June 30, 2024 (or anaphylaxis due to the influenza vaccine any time before December 31, 2024)</p> <p>Td/Tdap Rate: January 1, 2015 – December 31, 2024 (or anaphylaxis or encephalitis due to the Td/Tdap vaccine before December 31, 2024)</p> <p>Zoster Rate: One dose of the herpes zoster live vaccine or two doses of the herpes zoster recombination vaccine on or after the beneficiary's 50th birthday and by December 31, 2024 (or anaphylaxis due to the herpes zoster vaccine before December 31, 2024)</p> <p>Pneumococcal Rate: At least one dose of adult pneumococcal vaccine on or after the beneficiary's 19th birthday and by December 31, 2024 (or anaphylaxis due to the pneumococcal vaccine before December 31, 2024)</p>	January 1, 2024 – December 31, 2024 ^c
AAB-AD: Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis: Age 18 and Older	<p>Intake Period: July 1, 2023 – June 30, 2024</p> <p>Negative medication history review: June 1, 2023 – June 30, 2024 (30 days prior to the episode date)</p> <p>Negative comorbid condition history: July 1, 2022 – June 30, 2024 (365 days prior to and including the episode date [366 days total])</p>	July 1, 2023 – July 3, 2024 (Episode date through three days after episode date)	June 1, 2023 – July 3, 2024 (30 days prior to episode date through three days after episode date [34 total days])

Measure	2025 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
AMM-AD: Antidepressant Medication Management	Index prescription start date (IPSD): May 1, 2023 – April 30, 2024 Negative medication history review: January 16, 2023 – January 15, 2024 (105 days prior to the IPSD)	Acute Phase: May 1, 2023 – August 23, 2024 (IPSD through 114 days following IPSD) Continuation Phase: May 1, 2023 – December 18, 2024 (IPSD through 231 days following IPSD)	January 16, 2023 – December 18, 2024 ^c (105 days prior to IPSD through 231 days after the IPSD)
AMR-AD: Asthma Medication Ratio: Ages 19 to 64	January 1, 2023 – December 31, 2024	January 1, 2024 – December 31, 2024	January 1, 2023 – December 31, 2024 ^d
BCS-AD: Breast Cancer Screening	January 1, 2024 – December 31, 2024	October 1, 2022 – December 31, 2024	October 1, 2022 – December 31, 2024 ^e
CBP-AD: Controlling High Blood Pressure	January 1, 2023 – June 30, 2024	January 1, 2024 – December 31, 2024 ^f	January 1, 2024 – December 31, 2024 ^c
CCP-AD: Contraceptive Care – Postpartum Women Ages 21 to 44	Delivery Date: January 1, 2024 – September 30, 2024	3-Day Rates: January 1, 2024 – October 3, 2024 (Delivery date through 3 days after delivery date) ^g 90-Day Rates: January 1, 2024 – December 31, 2024 (Delivery date through 90 days after delivery date) ^g	January 1, 2024 – December 31, 2024 (Delivery date through 90 days after delivery date)
CCS-AD: Cervical Cancer Screening	January 1, 2024 – December 31, 2024	Ages 24–64: January 1, 2022 – December 31, 2024 Ages 30–64: January 1, 2020 – December 31, 2024	January 1, 2024 – December 31, 2024 ^d
CCW-AD: Contraceptive Care – All Women Ages 21 to 44	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024 ^c
CDF-AD: Screening for Depression and Follow-Up Plan: Age 18 and Older	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	None
CHL-AD: Chlamydia Screening in Women Ages 21 to 24	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024 ^c
COB-AD: Concurrent Use of Opioids and Benzodiazepines	Index Prescription Start Date (IPSD): January 1, 2024 – December 2, 2024	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024 ^h

Measure	2025 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
COL-AD: Colorectal Cancer Screening	January 1, 2024 – December 31, 2024	<p>Fecal occult blood test: January 1, 2024 – December 31, 2024</p> <p>Stool DNA (sDNA) with fecal immunochemical (FIT) test: January 1, 2022 – December 31, 2024</p> <p>Flexible sigmoidoscopy or CT colonography: January 1, 2020 – December 31, 2024</p> <p>Colonoscopy: January 1, 2015 – December 31, 2024</p>	January 1, 2023 – December 31, 2024 ^d
CPA-AD: Consumer Assessment of Healthcare Providers and Systems (CAHPS®) Health Plan Survey 5.1H, Adult Version (Medicaid)	Not applicable (varies by survey question; most questions reference “the last 6 months”)	Not applicable (varies by survey question; most questions reference “the last 6 months”)	July 1, 2024 – December 31, 2024 ⁱ
CPU-AD: Long-Term Services and Supports Comprehensive Care Plan and Update	<p>New Beneficiaries: Newly enrolled in long-term services and supports (LTSS) between August 1, 2023 and July 31, 2024 and enrolled on December 31, 2024</p> <p>Established Beneficiaries: Enrolled prior to August 1, 2023 and enrolled on December 31, 2024</p>	<p>Care Plan with Core Elements Documented</p> <p>New beneficiaries: August 1, 2023 – November 28, 2024 (Within 120 days of enrollment)</p> <p>Established beneficiaries: January 1, 2024 – December 31, 2024</p> <p>Care Plan with Supplemental Elements Documented</p> <p>New beneficiaries: August 1, 2023 – November 28, 2024 (Within 120 days of enrollment)</p> <p>Established beneficiaries: January 1, 2024 – December 31, 2024</p>	August 1, 2023 – December 31, 2024 (Enrolled for at least 150 days during this period)
EDV-AD: Ambulatory Care Sensitive Emergency Department Visits for Non-Traumatic Dental Conditions in Adults	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	None

Measure	2025 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
FUA-AD: Follow-Up After Emergency Department Visit for Substance Use: Age 18 and Older	Emergency department (ED) visit date: January 1, 2024 – December 1, 2024	7-Day Follow-up: January 1, 2024 – December 8, 2024 (ED visit date through 7 days after visit date) 30-Day Follow-up: January 1, 2024 – December 31, 2024 (ED visit date through 30 days after visit date)	January 1, 2024 – December 31, 2024 (ED visit date through 30 days after visit date)
FUH-AD: Follow-Up After Hospitalization for Mental Illness: Age 18 and Older	Discharge date: January 1, 2024 – December 1, 2024	7-Day Follow-up: January 2, 2024 – December 8, 2024 (7 days after discharge date) 30-Day Follow-up: January 2, 2024 – December 31, 2024 (30 days after discharge date)	January 1, 2024 – December 31, 2024 (30 days after discharge date)
FUM-AD: Follow-Up After Emergency Department Visit for Mental Illness: Age 18 and Older	ED visit date: January 1, 2024 – December 1, 2024	7-Day Follow-up: January 1, 2024 – December 8, 2024 (ED visit date through 7 days after visit date) 30-Day Follow-up: January 1, 2024 – December 31, 2024 (ED visit date through 30 days after visit date)	January 1, 2024 – December 31, 2024 (ED visit date through 30 days after visit date)
GSD-AD: Glycemic Status Assessment for Patients with Diabetes	January 1, 2024 – December 31, 2024 Diabetes diagnosis: January 1, 2023 – December 31, 2024	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024 ^c
HPCMI-AD: Diabetes Care for People With Serious Mental Illness: Glycemic Status >9.0%	January 1, 2024 – December 31, 2024 Diabetes diagnosis: January 1, 2023 – December 31, 2024	January 1, 2024 – December 31, 2024	January 1, 2024– December 31, 2024 ^c
HVL-AD: HIV Viral Load Suppression	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	None

Measure	2025 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
IET-AD: Initiation and Engagement of Substance Use Disorder Treatment	Substance use disorder (SUD) episode date: November 15, 2023 – November 14, 2024 Negative SUD diagnosis and medication history review: May 4, 2023 – November 14, 2024 (194 days prior to the SUD episode date)	Initiation of SUD Treatment: November 15, 2023 – November 28, 2024 (Within 14 days of the SUD episode date) ^j Engagement of SUD Treatment: November 16, 2023 – December 31, 2024 (Day after initiation encounter through 34 days after the initiation event) ^j	May 5, 2023 – December 31, 2024 (194 days prior to the SUD episode date through 47 days after the SUD episode date)
LRCD-AD: Low-Risk Cesarean Delivery: Age 20 and Older	Birth date: January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	None
MSC-AD: Medical Assistance with Smoking and Tobacco Use Cessation	Not applicable (includes survey respondents who currently smoke every day or some days)	Not applicable (references “the last 6 months”)	Year 1: July 1, 2023 – December 31, 2023 ⁱ Year 2: July 1, 2024 – December 31, 2024 ⁱ
NCIDDS-AD: National Core Indicators	July 1, 2024 – June 30, 2025	July 1, 2024 – June 30, 2025	None
OEVP-AD: Oral Evaluation During Pregnancy: Ages 21 to 44	Delivery date: January 1, 2024 – December 31, 2024	April 6, 2023 – December 30, 2024 (270 days prior to the delivery date)	July 5, 2023 – December 31, 2024 (180 days prior to delivery through the delivery date)
OHD-AD: Use of Opioids at High Dosage in Persons Without Cancer	Index Prescription Start Date (IPSD): January 1, 2024 – October 3, 2024	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024 ^h
OUD-AD: Use of Pharmacotherapy for Opioid Use Disorder	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024
PCR-AD: Plan All-Cause Readmissions	Index hospital stay (IHS) discharge date: January 1, 2024 – December 1, 2024	January 3, 2024 – December 31, 2024 (2 days through 30 days following IHS discharge date)	January 1, 2023 – December 31, 2024 (365 days prior to and including IHS discharge date through 30 days after the IHS discharge date) ^k

Measure	2025 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
PDS-AD: Postpartum Depression Screening and Follow-Up: Ages 21 and Older	Delivery date: September 8, 2023 – September 7, 2024	<p>Depression Screening: September 15, 2023 – November 30, 2024 (7 to 84 days following the delivery date)</p> <p>Follow-up on Positive Screen:</p> <ul style="list-style-type: none"> – September 15, 2023 – December 31, 2024 (On or up to 30 days after the date of the first positive screen [31 total days]) – September 15, 2023 – November 30, 2024 (Documentation of additional depression screening on the same day as a positive screen) 	September 8, 2023 – November 6, 2024 (On the delivery date through 60 days following the delivery date)
PPC2-AD: Prenatal and Postpartum Care: Age 21 and Older	Delivery date: October 8, 2023 – October 7, 2024	<p>Timeliness of Prenatal Care: Visit in the first trimester: January 1, 2023 – April 14, 2024 (176 to 280 days prior to delivery)</p> <p>Note: Women who were not continuously enrolled (with no gaps) from at least 219 days before delivery through 60 days after delivery must have a prenatal visit any time during the period that begins 280 days prior to delivery and ends 42 days after their enrollment start date (not including visits on or after the date of delivery).</p> <p>Postpartum Care: October 15, 2023 – December 30, 2024 (7 to 84 days after delivery date)</p>	August 26, 2023 – December 6, 2024 (43 days prior to delivery date through 60 days after delivery date)
PQI01-AD: PQI 01: Diabetes Short-Term Complications Admission Rate	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	None
PQI05-AD: PQI 05: Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Admission Rate	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	None

Measure	2025 Measurement Period ^a		
	Denominator ^b	Numerator	Continuous Enrollment Period
PQI08-AD: PQI 08: Heart Failure Admission Rate	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	None
PQI15-AD: PQI 15: Asthma in Younger Adults Admission Rate	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	None
PRS-AD: Prenatal Immunization Status: Age 21 and Older	Delivery date: January 1, 2024– December 31, 2024	Influenza Rate: July 1, 2023 – December 31, 2024 (or anaphylaxis due to the influenza vaccine any time before the delivery) Tdap Rate: March 6, 2023 - December 31, 2024 (During the pregnancy [including on the delivery date] or anaphylaxis or encephalitis due to the Tdap vaccine any time before the delivery)	December 4, 2023 – December 31, 2024 (28 days prior to the delivery date through the delivery date)
SAA-AD: Adherence to Antipsychotic Medications for Individuals with Schizophrenia	Index prescription start date (IPSD): January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024 (IPSD through December 31, 2024)	January 1, 2024 – December 31, 2024 ^c
SSD-AD: Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications	January 1, 2024 – December 31, 2024 Diabetes diagnosis: January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024	January 1, 2024 – December 31, 2024 ^c

^a For some measures, the measurement period for the numerator, denominator, or continuous enrollment period varies depending on a specified date for each enrollee (such as enrollee birthdates, prescription or treatment start dates, and discharge dates). For these measures, two ranges are shown. The first date range identifies the full range of possible dates that states will need to use to calculate the measure for all measure-eligible enrollees. The text in parentheses describes the measurement period that should be used for each eligible enrollee.

^b When reporting each measure to CMS, states should indicate whether they defined the measurement period according to Core Set specifications. For many measures, this date range corresponds to calendar year 2024 (January 1, 2024 – December 31, 2024). Some measures also require states to review utilization or enrollment prior to this period to identify the measure eligible population. For example, the AMM-AD measure instructs states to identify enrollees with antidepressant prescriptions that started May 1, 2023 through April 30, 2024 (the first date range). However, states will also need to review enrollee medication history for 105 days prior to the start of the index prescription (the second date range). States that followed the 2025 Adult Core Set specifications (that is, calculated the denominator using prescriptions from May 2023 through April 2024) should select “Yes, our state adhered to Core Set specifications in defining the measurement period for calculating this measure.” States that used a different date range, should answer “No” to this question and provide the Start Date and End Date they used to identify the Denominator (based on the first date range and not the look-back period). States should note variations from any measurement period (numerator, denominator, continuous enrollment) in the “Variations from Measurement Specifications” section.

^c No more than one gap in enrollment of up to 45 days during the continuous enrollment period.

^d No more than one gap in enrollment of up to 45 days during each year of the continuous enrollment period.

^e No more than one gap in enrollment of up to 45 days for each full calendar year of continuous enrollment. No gaps are allowed during the first three months of the continuous enrollment period (October 1, 2022 – December 31, 2022)

^f Blood pressure reading must occur on or after the date of the second diagnosis of hypertension.

^g Applies to both the Most or Moderately Effective Contraception rate and Long-Acting Reversible Contraception (LARC) rate.

^h No more than one gap in continuous enrollment of up to 31 days during the measurement year.

ⁱ No more than one gap in enrollment of up to 45 days during the last six months of the measurement year. In addition, the beneficiary must be enrolled in Medicaid or CHIP at the time of the survey.

^j Applies to all rates: Alcohol use disorder, Opioid use disorder, Other substance use disorder, and Total.

^k No more than one gap in enrollment of up to 45 days during the 365 days prior to the index discharge date and no gap during the 30 days following the index discharge date.